Release Date: May 8, 2025
Expiration Date: May 8, 2026
Activity Overview
Over the past decade, the treatment of biliary tract cancers (BTCs) has been fundamentally altered with the introduction of effective targeted and immunologic therapy approaches. Optimal treatment selection now depends on careful evaluation of various molecular alterations that may be present in individual cases.
This podcast features a discussion of adverse event (AE) profiles associated with different treatment approaches for metastatic, HER2-positive BTC. Led by Rohit Gosain, MD; and Rahul Gosain, MD; this clinical conversation features a faculty expert in evaluating and treating these cancers.
Target Audience
This educational activity is directed toward US and global community medical oncologists, pathologists, oncology nurses, nurse practitioners, and advanced practice providers who manage patients with GEA and BTC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review the common and severe adverse events observed with HER2-targeted agents and understand how patient-specific factors and prior therapies influence AE profiles in patients with BTC
- Apply clinical trial–informed approaches to AE monitoring and management, including premedication protocols, dose modifications, and multidisciplinary team coordination to optimize patient outcomes and adherence to HER2-targeted therapies
Rahul Gosain, MD, MBA
Medical Director of Wilmot Cancer Institute at Webster
Director of Wilmot Cancer Institute Regional Infusion Services
Assistant Professor of Clinical Medicine
Wilmot Cancer Institute - University of Rochester
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, MJH Life Sciences, Oncology News Central, SignifyMD.
Rohit Gosain, MD
Director of Roswell Park Care Network Southtowns
Assistant Professor of Clinical Medicine
Roswell Park Comprehensive Cancer Center - University at Buffalo
Rochester, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, MJH Life Sciences, Oncology News Central, SignifyMD.
Rachna T. Shroff, MD, MS, FASCO
Chief, Division of Hematology and Oncology
Chief, Section of GI Medical Oncology
Associate Director of Clinical Investigations, UACC
Professor of Medicine
The University of Arizona Cancer Center
Tucson, AZ
Disclosures: Consultant: AstraZeneca, Elevar Therapeutics, Genentech, ICON Clinical Research LLC.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.